9969 Share Price Performance
HK$15.05
6.41 (74.19%)
29.3% undervalued intrinsic discount
HK$21.27
Fair Value
Price HK$15.05
AnalystConsensusTarget HK$21.27
AnalystLowTarget HK$17.24
AnalystHighTarget HK$27.09
Fair ValueHK$21.27
Share Pricen/a
InnoCare Pharma Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
9969 Community Narratives
AN
Fair Value HK$21.27 29.3% undervalued intrinsic discount
Analysts Lift InnoCare Pharma Target Price as Margins and Revenue Outlook Improve
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value HK$17.24 12.7% undervalued intrinsic discount
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value HK$27.09 44.4% undervalued intrinsic discount
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
Key Takeaways Heavy dependence on a single drug and regulatory risks threaten profitability and revenue stability, especially if late-stage trials or approvals face setbacks. Heightened cost pressures, geopolitical barriers, and aggressive R&D outlays could limit global expansion, compress margins, and suppress future earnings per share.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
HK$17.24
12.7% undervalued intrinsic discount
Fair Value
Revenue
12.74% p.a.
Profit Margin
12.12%
Future PE
111.9x
Price in 2029
HK$21.29
Analysts Lift InnoCare Pharma Target Price as Margins and Revenue Outlook Improve
Key Takeaways Strong progress in drug commercialization and pipeline development suggests significant potential for future revenue growth and enhanced earnings. Strategic global expansion and innovative therapies aim to improve net margins and drive long-term revenue stability.Read more
46
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
HK$21.27
29.3% undervalued intrinsic discount
Fair Value
Profit Margin
2.6%
Future PE
529.22x
Price in 2029
HK$26.26
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
Key Takeaways Leadership in BTK inhibition and innovative drug pipeline positions the company for rapid, diversified revenue growth and major breakthroughs in multiple therapeutic areas. Strategic expansion into ADCs and strong operational efficiency create high-margin global opportunities, supporting long-term market dominance and sustained margin expansion.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
HK$27.09
44.4% undervalued intrinsic discount
Fair Value
Profit Margin
15.8%
Future PE
104.93x
Price in 2029
HK$33.44
Trending Discussion
Recently Updated Narratives
AN
9969: Autoimmune And Pediatric Oncology Pipeline Progress Will Support Undervalued Shares
Fair Value: HK$17.24 12.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
9969: Advancing Autoimmune Trials And 2025 Profitability Shift Will Support Upside Potential
Fair Value: HK$21.27 29.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
9969: Pediatric Cancer Breakthrough And 2025 Profit Shift Will Drive Repricing
Fair Value: HK$27.09 44.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
InnoCare Pharma Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 23, 2026
- 0.38
- 91.95%
- 27.05%
- 20.2%
About 9969
- Founded
- 2015
- Employees
- 1176
- CEO
- WebsiteView website
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
